University of Toronto receives $35 million to modernize high containment facility.
Welcome to EPIC – The Emerging and Pandemic Infections Consortium.
EPIC Partners play an integral role in infectious disease research, from work that controlled diphtheria and helped eradicate smallpox 100 years ago, to current research in antimicrobial resistance and infection control.
Today, our collective fight against infectious threats, including COVID-19, highly pathogenic avian influenza and mpox, makes clear that there’s never been a more important time to advance EPIC – the Emerging and Pandemic Infections Consortium as a critical hub in the pan-Canadian effort to combat future pandemics.
Building on our momentum in combatting the SARS-CoV-2 virus, EPIC will marshal the advanced research infrastructure and the world-renowned research and training expertise of the EPIC Partners to allow an integrated innovative response to infectious diseases.
EPIC is a collaborative initiative among:
- University of Toronto
- The Hospital for Sick Children (SickKids)
- Lunenfeld-Tanenbaum Research Institute
- Sunnybrook Research Institute
- University Health Network
- Unity Health Toronto
These globally-leading institutions will make a difference to preventing the next pandemic and enhancing the impact of the life sciences ecosystem in Ontario.
These are the four pillars of EPIC’s work
Toronto High Containment Facility
Toronto’s only Combined Containment Level 3 (C-CL3) facility for the study of high-risk human pathogens has been critical to understanding the viral pathogens and developing therapeutics and treatments. Infectious diseases continue to pose a threat to Canadians’ health and prosperity. Investments in the facility will prepare Ontario and Canada for future pandemics.
Training & Talent
EPIC offers immersive and cross-disciplinary training to a diverse cohort of talent researching infectious diseases, who are ready to work in industry and academia. Hundreds of researchers, clinicians and lab staff will gain access to leading-edge technologies, develop the skills to turn discovery into solutions, and connect Canada to global networks of pandemic surveillance and response.
Transformative Research
EPIC will connect multiple disciplines to address infectious diseases. Insights made possible by state-of-the-art platforms that accelerate the discovery and production of therapies will combine with the expertise of clinicians, engineers, public health experts and scientists to translate treatments to patients and improve their outcomes.
Knowledge Translation
EPIC will play an important role as a knowledge broker. It will create a hub for potential commercialization of novel therapeutics. New researchers at EPIC will be equipped to explain bench science to decision-makers and the public, as well as to translate discoveries into made-in-Canada products and solutions to global health challenges.
84 weeks
Estimated number of weeks required to clear surgery backlogs in Ontario.
%
$26B
Amount (in Billions) that Canada’s federal government is targeting for health and biosciences exports by 2025.
EPIC News
Member Spotlight: Shelly Bolotin
For this member spotlight, we welcome Shelly Bolotin, an associate professor at the Dalla Lana School of Public Health and in the department of laboratory medicine and pathobiology at the University of Toronto’s Temerty Faculty of Medicine. Shelly is also a scientist a Public Health Ontario and the director of the Centre for Vaccine Preventable Diseases, which aims to catalyze cutting-edge research and education that maximizes the health benefits of immunization for everyone.
Member Spotlight: Shelly Bolotin
For this member spotlight, we welcome Shelly Bolotin, an associate professor at the Dalla Lana School of Public Health and in the department of laboratory medicine and pathobiology at the University of Toronto’s Temerty Faculty of Medicine. Shelly is also a scientist a Public Health Ontario and the director of the Centre for Vaccine Preventable Diseases, which aims to catalyze cutting-edge research and education that maximizes the health benefits of immunization for everyone.
Can “sleeping” bacteria spread antibiotic resistance genes?
Today over sixty-five per cent of human infections are due to bacterial infections. Antibiotic resistance, when bacteria can defeat the drugs designed to kill them, is a serious health problem and remains a top concern for many clinicians and researchers. That’s why Celine Levesque’s lab has been studying how bacteria are able to survive in different conditions. Recently, together with senior research associate Delphine Dufour, they found that bacteria can pass on antibiotic-resistant DNA to other cells in the mouth. Although Levesque’s research heavily focuses on Streptococcus mutans (the bacteria responsible for cavities), their recent findings have implications that go well beyond oral health.
How bending implantable medical devices can enable infectious organisms to gain a toehold
A study from U of T Engineering researchers shows that mechanical deformation of medically implantable materials — such as bending or twisting — can have a big impact on the formation of potentially harmful biofilms. The study, described in a paper published in Scientific Reports, shows that even slight bending of elastomeric materials such as polydimethylsiloxane (PDMS), also known as silicone, opens up microscopic cracks that are perfect environments for colonizing bacteria.